2nd World Congress on Controversies in Ophthalmology 2011: Post-Conference Review and Analysis

Publication date: March 2012

Keywords : diabete, Diabetic retinopathy, Keratoconjunctivitis, glaucoma

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.

The annual meeting of the 2nd World Congress on Controversies in Ophthalmology was held in the Catalonia Palace of Congresses, Barcelona, Spain, between March 3 and 6, 2011. The four day conference included discussion on controversies related to the treatment of cataract, cornea and external diseases, glaucoma, neuro-ophthalmology, refractive surgery, retina and uveitis. The report titled “” aimed to cover the scientific sessions and articles after completion of the conference.

Scope of the Research

The report provides complete coverage of conference. Its

Scope of the Research includes -
- Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key industry dynamics and future treatment paradigm.
- Review of pre- and post-conference KOL/analyst comments
- Industry revenue data for 2010 and projection forward to 2017 for a specific disease area (if the conference being covered is focused on a specific disease area).
- Review of key market trends and events which are likely to impact and change the dynamics of the concerned disease industry s in the long run.

Why Should You Get This Report?

The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies by understanding the trends and developments that are driving or are expected to drive the industry in the concerned disease areas.
- Explore Merger and Acquisition opportunities by identifying key products and industry players.
- Develop successful market-entry strategies .
- Identify key players best positioned to take advantage of the industry opportunities.
- Make more informed business decisions from the insightful and in-depth analysis of the industry and the factors influencing the same.

Global Pathology Industry

1 Table of contents

I Table of contents 3
I. 1 List of Data tables 3
I. 2 List of Charts 3

II 2nd World Congress on Controversies in Ophthalmology: Post-Conference Key Highlights 4
II. 1 Efficacy of Dexamethasone Intravitreal Implant for the Treatment of Uveitis Based On Patient-Reported Vision Function Outcome Measures 4
II. 2 Safety Company Profile: Preservatives Containing Intracameral Phenylephrine 4
II. 3 Treat AMD with VEGF Suppression 5
II. 4 Topical Bevacizumab for Corneal Neovascularization and Neovascular Glaucoma 6
II. 5 Effectiveness and Tolerability of Bimatoprost 0.01% in a Large Population of Patients with Glaucoma or Ocular Hypertension Treated In Clinical Practice in Germany 6
II. 6 Systemic Bevacizumab (Avastin) For Exudative Retinal Detachment Secondary to Choroidal Melanoma 7
II. 7 The Effect of Sub-Tenon's Infusion of Triamcinolone Acetonide on Glycemic Control, Plasma Cortisol and Adrenocorticotropic Hormone Levels in Patients with Diabetic Macular Edema: A Pilot Study 7
II. 8 Debate: Avastin vs. Lucentis vs. others 8
II. 9 Iluvien Intravitreal Insert (Fluocinolone Acetonide) For Diabetic Macular Edema (FAME): Phase III Results 10
II. 10 Design and Rational Of Como: A 12-Month Masked Study That Compares the Safety and Efficacy of Ozurdex versus Lucentis (Ranibizumab) in Branch Retinal Vein Occlusion 10
II. 11 Controversies in Incidence of Infectious Corneal Ulcers in Developed Countries, Portsmouth Study, UK 11
II. 12 Debate: The Role of Adjunctive Treatment in Age-Related Macular Degeneration 11
II. 13 Floppy Eyelid Syndrome: Epidemiological and Clinical Studies 12
II. 14 Oral Propranolol for Circumscribed Choroidal Haemangioma: A Case Report on 10-Month Follow-Up 13
II. 15 Ethambutol Induced Optic Neuropathy 13

III Abbreviations 14

IV Disclaimer 15

1.1 List of Data tables
Data table 1: Treatment Pattern of VEGF Suppression in AMD 5

1.2 List of Charts

Chart 1: Macular Degeneration Therapeutics March ket, Global, Market Overview and Potential Size and Forecasted data ($bn), 2009–2017 9

Eye Disease in World